% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • lengrasso lengrasso Apr 20, 2014 3:09 PM Flag

    M.I.T. Technology Review - April 16, 2014

    "Nelsen’s office granted licenses to use the interfering RNA technology to different groups, with different sorts of permission. A startup called Alnylam got an exclusive license to use the technology to try to develop treatments for patients. In addition, MIT granted non-exclusive licenses to a few companies that wanted to sell the molecular components of the gene-silencing technique.

    Sentiment: Hold

75.57-1.52(-1.97%)Sep 23 4:00 PMEDT